The potential use of PARP inhibition in human melanomas has been further supported by a recent retrospective cohort study of 66 patients with metastatic melanoma treated with conventional chemotherapy using DNA alkylating compounds (Abecassis et al., 2019). This evidence concerns the gene PARP1 and melanoma.